Literature DB >> 28012509

Changes in the inner ear structures in cystic fibrosis patients.

Henrique F Pauna1, Rafael C Monsanto2, Natsuko Kurata3, Michael M Paparella4, Sebahattin Cureoglu5.   

Abstract

OBJECTIVE: Although prolonged use of antibiotics is very common in cystic fibrosis (CF) patients, no studies have assessed the changes in both cochlear and peripheral vestibular systems in this population.
METHODS: We used human temporal bones to analyze the density of vestibular dark, transitional, and hair cells in specimens from CF patients who were exposed to several types of antibiotics, as compared with specimens from an age-matched control group with no history of ear disease or antibiotic use. Additionally, we analyzed the changes in the elements of the cochlea (hair cells, spiral ganglion neurons, and the area of the stria vascularis). Data was gathered using differential interference contrast microscopy and light microscopy.
RESULTS: In the CF group, 83% of patients were exposed to some ototoxic drugs, such as aminoglycosides. As compared with the control group, the density of both type I and type II vestibular hair cells was significantly lower in all structures analyzed; the number of dark cells was significantly lower in the lateral and posterior semicircular canals. We noted a trend toward a lower number of both inner and outer cochlear hair cells at all turns of the cochlea. The number of spiral ganglion neurons in Rosenthal's canal at the apical turn of the cochlea was significantly lower; furthermore, the area of the stria vascularis at the apical turn of the cochlea was significantly smaller.
CONCLUSIONS: Deterioration of cochlear and vestibular structures in CF patients might be related to their exposure to ototoxic antibiotics. Well-designed case-control studies are necessary to rule out the effect of CF itself.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Antibiotics; Cochlear cells; Cystic fibrosis; Inner ear changes; Vestibular cells

Mesh:

Substances:

Year:  2016        PMID: 28012509      PMCID: PMC5344023          DOI: 10.1016/j.ijporl.2016.11.013

Source DB:  PubMed          Journal:  Int J Pediatr Otorhinolaryngol        ISSN: 0165-5876            Impact factor:   1.675


  33 in total

1.  Histopathologic inner ear changes in deafness due to neomycin.

Authors:  J R LINDSAY; L R PROCTOR; W P WORK
Journal:  Laryngoscope       Date:  1960-04       Impact factor: 3.325

Review 2.  The role of routine hearing screening in children with cystic fibrosis on aminoglycosides: A systematic review.

Authors:  Zainab Farzal; Yann-Fuu Kou; Rachel St John; Gopi B Shah; Ron B Mitchell
Journal:  Laryngoscope       Date:  2015-07-07       Impact factor: 3.325

3.  Ototoxicity of amikacin.

Authors:  R E Black; W K Lau; R J Weinstein; L S Young; W L Hewitt
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

4.  Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis.

Authors:  S S Pedersen; T Jensen; D Osterhammel; P Osterhammel
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

5.  The ototoxicity of kanamycin. A comparative histopathological study.

Authors:  G J Matz; T H Wallace; P H Ward
Journal:  Laryngoscope       Date:  1965-11       Impact factor: 3.325

Review 6.  New developments in aminoglycoside therapy and ototoxicity.

Authors:  Jing Xie; Andra E Talaska; Jochen Schacht
Journal:  Hear Res       Date:  2011-05-27       Impact factor: 3.208

7.  Cupular deposits and aminoglycoside administration in human temporal bones.

Authors:  Takeshi Kusunoki; Sebahattin Cureoglu; Patricia A Schachern; Mehmet F Oktay; Hisaki Fukushima; Michael M Paparella
Journal:  J Laryngol Otol       Date:  2005-02       Impact factor: 1.469

8.  A method for quantitative assessment of vestibular otopathology.

Authors:  S N Merchant
Journal:  Laryngoscope       Date:  1999-10       Impact factor: 3.325

9.  Ear disease is not a common complication in cystic fibrosis.

Authors:  M Cipolli; M Canciani; M Cavazzani; P Uras; P Zampieri; G Mastella
Journal:  Eur J Pediatr       Date:  1993-03       Impact factor: 3.183

10.  Minimisation of aminoglycoside toxicity in patients with cystic fibrosis.

Authors:  P J Wood; L L Ioannides-Demos; S C Li; T J Williams; B Hickey; W J Spicer; R E Hooper; A J McLean
Journal:  Thorax       Date:  1996-04       Impact factor: 9.139

View more
  3 in total

1.  Functional Impacts of Aminoglycoside Treatment on Speech Perception and Extended High-Frequency Hearing Loss in a Pediatric Cystic Fibrosis Cohort.

Authors:  Chelsea M Blankenship; Lisa L Hunter; M Patrick Feeney; Madison Cox; Lindsey Bittinger; Angela C Garinis; Li Lin; Gary McPhail; John P Clancy
Journal:  Am J Audiol       Date:  2021-01-19       Impact factor: 1.636

2.  Wideband Acoustic Reflex Growth in Adults With Cystic Fibrosis.

Authors:  Martha R Westman; Daniel B Putterman; Angela C Garinis; Lisa L Hunter; M Patrick Feeney
Journal:  Am J Audiol       Date:  2021-03-04       Impact factor: 1.636

3.  Tobramycin and vestibulotoxicity: retrospective analysis of four cases.

Authors:  S E M Vonk; E J M Weersink; C J Majoor; E M Kemper
Journal:  Eur J Hosp Pharm       Date:  2021-03-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.